Physician profile
Kewan Hamid
NPI 1366896706
$8,685.20
in general payments reported to CMS, 2019-2025
25 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $302 · 2023: $273 · 2024: $5,940 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,580 · Food and Beverage: $2,831 · Travel and Lodging: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,579.99 |
| Food and Beverage | $2,830.67 |
| Travel and Lodging | $762.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,347.60 | 2024 | |
| Glaxosmithkline, LLC. | $565.68 | 2024-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Actelion Pharmaceuticals US, INC. | $499.94 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $495.32 | 2022-2025 | Tezspire, Breztri, Fasenra |
| United Therapeutics Corporation | $309.80 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Insmed, INC. | $189.28 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $153.34 | 2024-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $138.79 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.20 | 2022-2025 | Ofev |
| Jazz Pharmaceuticals INC. | $122.67 | 2024-2025 | |
| Vifor Pharma, INC. | $111.35 | 2025 | Zemaira |
| Electromed, INC. | $96.39 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $90.63 | 2025 | Zerbaxa |
| Genzyme Corporation | $69.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.56 | 2025 | Glassia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $54.78 | 2025 | Yupelri |
| Sandoz INC. | $49.30 | 2021-2023 | Treprostinil |
| Alexion Pharmaceuticals, INC. | $43.46 | 2021-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $28.11 | 2021-2023 | |
| Amgen INC. | $26.19 | 2025 | Tezspire |
| Baxter Healthcare | $25.74 | 2022 | |
| Verona Pharma, INC. | $20.15 | 2025 | Ohtuvayre |
| Shionogi INC | $18.95 | 2023 | Fetroja |
| Axsome Therapeutics, INC. | $18.62 | 2025 | Sunosi |
| Philips North America LLC | $15.66 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kewan Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.